Law360, New York (September 13, 2012, 7:19 PM ET) -- In July 2012, Neogenix Oncology Inc., a biotech firm based in Rockville, Md., and New York, surprised investors by filing for Chapter 11 bankruptcy protection.[1] To those in the biotech industry, Neogenix, by all accounts, was a successful company with more than 500 shareholders and what seemed to be numerous clinical developments. Perhaps even more surprising than the actual Chapter 11 filing was the reason behind it.
It seems an inquiry by the U.S. Securities and Exchange Commission in late 2011 into the company’s capital raising...
Neogenix — A Cautionary Tale
To view the full article, take a free trial now.
